One line of research has succeeded to replicate in the laboratory the anatomy of specific blood vessels Using images of each patient, the images are 3D printed in microscopic format. These mini-arteries allow observation, under a microscope, of how blood circulates and how clots develop under controlled conditions.
The method, developed by a team at the University of Sydney, creates carotid artery remnants in about two hours Using CT scans, they generate "array-on-a-chip" devices that study the behavior of platelets and thrombi with a level of detail that is not possible to achieve in vivo. To do this, they use ultra-fast 3D printing and micromodeling on glass.
How microprinting on glass works
The research, published in the journal Advanced materialsIt is based on a rapid microfabrication technique on glass substrates that preserves the microtopography of the arterial wall, including irregularities and ulcers, and reproduces the flow dynamics on a microscopic scale.
Clinical scans are generated custom models which are reduced to approximately 200-300 micrometers. This size allows for tests to be performed under a microscope, introducing blood or analogues and controlling pressure and flow parameters to observe situations that would be risky to reproduce in the human body.
- From image to chip: 3D reconstruction of the artery from the patient's CT scan.
- Material 3D printing and micromolding on glass with high geometric fidelity.
- Essay: adjustments of shear and tension to simulate different flow patterns.
- Measurement: real-time monitoring of platelets and clots under the microscope.
What does it contribute to the study of thrombotic stroke?
The authors describe that friction forces and the flow tension on the arterial wall influences platelet movement. In regions of high mechanical stress, this was observed among seven to ten times more platelet displacement, a behavior related to aggregation and thrombus formation.
These findings help to understand how the vascular anatomy and factors such as hypertension or atherosclerosis They can favor the formation of a blood clot in a specific location. The platform opens the door to try anticoagulants or antiplatelet drugs in specific replications of each patient already reduce, in part, the dependence on animal models.
The team is also aiming for integration with Artificial Intelligence to build digital twins that predict stroke risk and guide personalized therapies. The combination of clinical scanning, ultrafast 3D printing, and microscopic observation could become a clinical decision support tool if it is validated in real-world environments.
It is important to note that this is a laboratory solution and will require clinical validation and standardization before its use in clinical practice. Aspects such as variability between patients, the materials used, and the scale of manufacturing will determine its adoption.
Potential impact in Spain and Europe
For healthcare systems of Spain and EuropeSuch a platform could help profile the risk of patients with carotid stenosis and select treatments more precisely. Many hospitals already have one. advanced imaging (CT, MRI) that could be integrated into this workflow.
This approach aligns with European initiatives to Horizon Europe and personalized medicineas well as with digital twin projects in healthcare. It could also boost collaborations between hospitals, bioengineering centers, and medtech companies specializing in lab-on-a-chip.
Clinical data management will require guarantees of Privacy and GDPR complianceIn addition to clear informed consent procedures, defining interoperable protocols and forming multidisciplinary teams that bring together clinicians, engineers, and AI experts will be key.
In parallel, the European regulatory path will require robust evidence and, where applicable, CE marking for associated devices or software. The real impact will depend on demonstrating clinical utility, cost-effectiveness, and ease of integration into daily practice.
These “arteries on a chip” based on 3D printed blood vessels They offer a promising way to study why certain clots form and how to prevent them, with the potential to accelerate drug trials and move towards more precise stroke management in European settings.
